Keywords: Merck & Co, Ariad Pharma, Taltorvic, Ridaforolius, USA, FDA advisory panel, Soft tissue sarcoma

Thumbs down for Merck & Co and Ariad sarcoma drug Taltorvic from FDA advisory

Article | 21 March 2012

• Print This

The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) yesterday voted by 13 to one against approving Taltorvic (ridaforolimus), ...

Enjoying this article? To continue reading you need to login or subscribe.